Pharmaceutical Technology
FEBRUARY 24, 2023
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. You can compare timelines.
pharmaphorum
AUGUST 4, 2022
Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks. The pandemic raised the sector’s profile and has helped establish pharma as a desirable career path for several reasons, including job security, innovation, and societal value.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 19, 2022
3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. This is reflected in the legal basis for biosimilars under Article 6 of Regulation 726/2004 and Article 10(4) of Directive 2001/83 (as amended by Directive 2004/27).
Contrarian Sales Techniques
FEBRUARY 23, 2023
However, it was later discovered that the drug increased the risk of heart attacks and strokes, and it was eventually pulled from the market in 2004. Another example is the case of Purdue Pharma and the opioid crisis. No sale is worth risking your health or safety.
European Pharmaceutical Review
JULY 5, 2022
Oncoral (Ascelia Pharma) is a novel patented tablet formulation of irinotecan, currently in Phase II clinical development, for daily dosing at home. Secondary endpoints will include response rate, overall survival, pharmacokinetics, safety and tolerability. J Clin Oncol, 2004; 22(14): 2849-2855. About the author.
PM360
SEPTEMBER 28, 2022
This was back in 2004/2005 when we were just hearing about biosimilars for the first time and they were the great unknowns. But now the big pharma companies have also jumped into the game. Ultimately, we want to establish ourselves as that one specialty pharma company in the U.S. So their battle test is high.
PM360
SEPTEMBER 15, 2022
Can more than 20 pharma companies unite around messaging for biomarker testing even though everyone seems to call it something different? Historically, pharma companies only do marketing for biomarker testing related to the type of drug they were launching,” says Nikki Martin, Senior Director, Precision Medicine Initiatives, LUNGevity. “As
Expert insights. Personalized for you.
64 
Let's personalize your content